ClearPoint Neuro announced successful registration of its Neuro Navigation portfolio with the Brazilian regulatory body, Agencia Nacional de Vigilancia Sanitaria, or ANVISA.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLPT:
- ClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil
- ClearPoint Neuro extends license and research pact with Philips
- ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS
- ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform
- ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results
Questions or Comments about the article? Write to editor@tipranks.com